AI Article Synopsis

  • Dopamine D3 receptors (D3Rs) play a key role in modulating brain activity, particularly in the hippocampus, which is crucial for memory and learning.
  • Blocking or removing D3Rs in mice enhances synaptic activity and improves long-term memory formation by strengthening synaptic connections through the cAMP/PKA signaling pathway.
  • In aged mice, D3Rs show a decline in axon terminals but remain stable in dendrites, and blocking these receptors can reverse memory and synaptic deficits, highlighting their potential as a target for treating cognitive decline in older individuals.

Article Abstract

Dopamine D3 receptors (D3Rs) modulate neuronal activity in several brain regions including the hippocampus. Although previous studies reported that blocking D3Rs exerts pro-cognitive effects, their involvement in hippocampal synaptic function and memory in the healthy and aged brain has not been thoroughly investigated. We demonstrated that in adult wild type (WT) mice, D3R pharmacological blockade or genetic deletion as in D3 knock out (KO) mice, converted the weak form of long-term potentiation (LTP1) into the stronger long-lasting LTP (LTP2) via the cAMP/PKA pathway, and allowed the formation of long-term memory. D3R effects were mainly mediated by post-synaptic mechanisms as their blockade enhanced basal synaptic transmission (BST), AMPAR-mediated currents, mEPSC amplitude, and the expression of the post-synaptic proteins PSD-95, phospho(p)GluA1 and p-CREB. Consistently, electron microscopy revealed a prevalent expression of D3Rs in post-synaptic dendrites. Interestingly, with age, D3Rs decreased in axon terminals while maintaining their levels in post-synaptic dendrites. Indeed, in aged WT mice, blocking D3Rs reversed the impairment of LTP, BST, memory, post-synaptic protein expression, and PSD length. Notably, aged D3-KO mice did not exhibit synaptic and memory deficits. In conclusion, we demonstrated the fundamental role of D3Rs in hippocampal synaptic function and memory, and their potential as a therapeutic target to counteract the age-related hippocampal cognitive decline.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11561665PMC
http://dx.doi.org/10.1111/acel.14291DOI Listing

Publication Analysis

Top Keywords

hippocampal synaptic
12
synaptic function
12
dopamine receptors
8
blocking d3rs
8
function memory
8
post-synaptic dendrites
8
d3rs
6
synaptic
5
memory
5
post-synaptic
5

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Columbia University, New York, NY, USA.

Background: Focused ultrasound (FUS)-induced blood-brain barrier opening (BBBO) is a technique for safely, non-invasively, and transiently opening the blood brain barrier in a targeted area of the brain. Pre-clinical and clinical studies have shown that FUS is capable of decreasing amyloid plaque load and stimulating neurogenesis in Alzheimer's Disease (AD) models, in addition to being safe for use in human patients. However, the effect of FUS-BBBO on neurons has not yet been characterized, despite its crucial role in cognition and regulating brain function.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Department of Neurology, Mayo Clinic, Rochester, MN, USA.

Background: Alzheimer's disease (AD) is an age-dependent neurodegenerative disorder with limited treatment options. As it progresses, synapse degeneration is the most important feature contributing to cognitive dysfunction. Mitochondria supply synapses with ATP for neurotransmitter release and vesicle recycling and buffer calcium concentrations.

View Article and Find Full Text PDF

Background: Alzheimer's disease (AD) is a neurodegenerative disorder without a cure. Targeting this multifactorial disease by repurposing FDA approved drugs serves as a faster mode of treatment due to its pre-established human safety. We tested terazosin (TZ), an a-1 adrenergic receptor (AR) antagonist and phosphoglycerate kinase-1 (PGK1) activator as having potential to treat AD.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Rush University Medical Center, Chicago, IL, USA.

Background: Alzheimer's disease is the most dreaded multifactorial neurological illness for which there is currently no known treatment. Although the exact cause of AD is still unknown, several factors related to lifestyle, genetics, and environment are known to have a significant role in the disease's development. Alzheimer's disease is characterized by neuronal loss, neurofibrillary tangles, and senile plaques.

View Article and Find Full Text PDF

Background: Diabetic conditions are associated with alterations in brain functions like memory deficits through processes like synaptic dysfunction in the hippocampus. Administering a combination of silver nanonaringenin and vitamin E appears promising since they are known to prevent diabetes and memory deficits in previous studies, and nanoformulation of naringenin may be one way to improve delivery and bioavailability of naringenin in the brain. This study investigated the effects of co-administering silver nanonaringenin and vitamin E against memory deficits and synaptic dysfunction in the hippocampus of a mice model of high-fat diet and streptozotocin (HS).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!